Microbicide Trials Network

MTN-020 - ASPIRE


A Study to Prevent Infection with a Ring for Extended Use – was a Phase III study to determine whether a vaginal ring containing the ARV drug dapivirine is a safe and effective method for protecting against the sexual transmission of HIV when used by women for a month at a time. ASPIRE enrolled 2,629 sexually active HIV-negative women ages 18-45 and was conducted between August 2012 and June 2015 at 15 clinical research sites in Malawi, Uganda, South Africa and Zimbabwe. Results, reported in February 2016, found HIV risk was reduced by 27 percent overall – there were 27 percent fewer women who acquired HIV in the group assigned to use the dapivirine ring than in the placebo ring group. There was a 37 percent reduction in HIV infections in a second analysis planned early into the study that excluded data from two sites with less than ideal retention and adherence. HIV risk was cut by more than half (56 percent) in women older than 21, who also appeared to use the ring most consistently. Additional analyses suggest even higher levels of protection can be achieved with regular and consistent use. The ring was developed by International Partnership for Microbicides (IPM), which conducted another Phase III trial, The Ring Study, in parallel with ASPIRE.

 

Results

HOPE open-label study of vaginal ring for preventing HIV begins

for former ASPIRE participants

18-July-2016

 

Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE

18-July-2016

 

After ASPIRE: HOPE and other MTN Studies of the Dapivirine Ring

18-July-2016

 

Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial

22-February-2016

     

ASPIRE Q&A on Results

22-February-2016

 

ASPIRE Results At-A-Glance

22-February-2016

 

See Also

Two Large Studies Show IPM’s Monthly Vaginal Ring Helps Protect Women Against HIV

22-February-2016

 

Sister Studies: The Ring Study and ASPIRE

22-February-2016

 

Other Study Milestones

Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women; results are expected early 2016

29-June-2015

 

ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women

26-June-2014

 

Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women

24-July-2012

 

See Also

MTN-020 – ASPIRE Protocol